Published in Hepatology on December 01, 2006
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology (2009) 1.11
SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients. Proteomics (2012) 1.11
Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol (2008) 1.04
Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol (2009) 0.97
Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon (2012) 0.97
The accuracy of sonography in predicting steatosis and fibrosis in chronic hepatitis C. Dig Dis Sci (2008) 0.96
Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation. Ther Clin Risk Manag (2008) 0.96
Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol (2009) 0.92
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther (2008) 0.91
A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol (2011) 0.90
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Hepatitis C Viral Kinetics in Special Populations. Curr Hepat Rep (2008) 0.90
Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int (2015) 0.87
Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol (2015) 0.85
Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int (2007) 0.84
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. J Virol (2015) 0.81
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol (2015) 0.77
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr (2011) 0.77
Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract (2014) 0.77
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PLoS One (2016) 0.76
Treatment options for HCV nonresponders and relapse patients. Gastroenterol Hepatol (N Y) (2010) 0.76
Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med (2015) 0.76
Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clin Proteomics (2016) 0.75
Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. Hepatology (2007) 0.75
The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. Gastroenterol Hepatol (N Y) (2007) 0.75
Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention. Case Rep Gastroenterol (2010) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
[New strategies for a better use of peginterferon and ribavirin and new drugs with specifically-targeted antiviral therapy for chronic hepatitis C]. Acta Gastroenterol Latinoam (2007) 0.75
Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol (2017) 0.75
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C. Dig Dis Sci (2011) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health. Soc Sci Med (2005) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med (2007) 5.13
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin (2012) 3.58
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med (2012) 3.28
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08